Pharmaceutical Technology Editors

Ascend Laboratories and Masters Pharmaceuticals cited in seizure of $11 million in unapproved drugs.

Hospira has recalled one lot of labetalol hydrochloride injection, USP, due to visible particulates.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

SGS makes two senior appointments at its new GMP/GLP laboratory in Carson, California.

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

EMA opens registration for it's sixth annual workshop on pediatric drug research and development.

FDA and EMA release a draft joint proposal on the development of new drugs to treat Gaucher disease in children.

Boehringer Ingelheim announced that it is working on a program to make clinical trial data and other related documents more widely accessible for approved products and drug-development programs that have been terminated.

EMA and ECHA sign agreement to share information and work together on risk assessments.

Hillary Clinton will deliver a keynote address at the 2014 BIO International Convention in San Diego.

New manufacturing capacity at the Le Mans, France facility is being used to scale up antibody drug conjugates.

Santen will purchase Merck's ophthalmology products business in Japan and key markets in Europe and Asia Pacific.

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

Draft guidance addresses the use of clinical pharmacology studies to determine biosimilarity of biologics.

FDA clarifies stability data recommendations for abbreviated new drug applications.

Garvey's vial-drying system and pressure-less accumulator reduces drying time and decreases the risk of vial damage.

Eurofins Scientific will acquire ViraCor-IBT Laboratories for $255 million.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

The Fogarty International Center, a component of the US NIH, calls for a focus on noncommunicable diseases and implementing science in low-resource settings.

A multi-institutional effort will fight pediatric leukemia and neuroblastoma.

FDA releases draft guidance on the development of drugs to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia.

The Pediatric Clinical Research Group initiative expands to include pediatric research sites.

MPI Research, inviCRO, and 3D Imaging open its new Translational Imaging Center in Michigan.

Ash Stevens receives the 2014 Lilly Global Supplier Award.

Pharmatek develops two new cGMP manufacturing suites for API-in-capsule productions.

AstraZeneca rejects $106 billion offer; Pfizer states its case for the merger with British government.

WHO report provides a comprehensive picture of antibiotic resistance and suggests strategies to fight resistance.

The Azzur Group and BioSPEQ merger will increase consulting services and project resources within the life-sciences industry.

Gallus BioPharmaceuticals enters a cell line optimization and manufacturing agreement with Omni Bio Pharmaceutical.